SCHEMBL7858

SCHEMBL7858

CC(=O)NCCc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.69
F13A1 P00488 1/20 0.69
SMN1; SMN2 Q16637 4/20 0.66
ALDH1A1 P00352 4/20 0.66
HPGD P15428 2/20 0.66
CA12 O43570 2/20 0.63
CA2 P00918 2/20 0.63
CA9 Q16790 2/20 0.63
EPHX1 P07099 1/20 0.61
NPC1 O15118 4/20 0.61
RAB9A P51151 4/20 0.61
MAPT P10636 2/20 0.61
PLAAT5 Q96KN8 1/20 0.59
PLAAT4 Q9UL19 1/20 0.59
CA1 P00915 1/20 0.59
MMP1 P03956 1/20 0.59
MMP2 P08253 1/20 0.59
MMP3 P08254 1/20 0.59
TAAR1 Q96RJ0 1/20 0.58
LMNA P02545 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31736052 0.98 KDM4E (0.67) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL7356956 0.94 KDM4E (0.62) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL1908713 0.93 EPHX1 (0.69) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL3861314 0.91 KDM4E (0.59) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10592850 0.89 KDM4E (0.84) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10066080 0.89 KDM4E (0.66) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL422827 0.88 L3MBTL1 (0.68) KDM4ESMN1; SMN2HPGDEPHX1NPC1
SCHEMBL13073755 0.87 ALDH1A1 (0.57) KDM4EF13A1SMN1; SMN2ALDH1A1HPGD
SCHEMBL15550563 0.87 HDAC3 (0.68) KDM4EF13A1HPGDTAAR1LMNA
SCHEMBL425223 0.86 TRPV1 (0.65) SMN1; SMN2ALDH1A1HPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 734 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118812429-A Preparation method of 1-methyl-1, 2,3, 4-tetrahydroisoquinoline 常州夏青科技有限公司 2024-10-22 CN claimed
CN-110403931-B Medical application of 5-hydroxyflavone substituted N-phenethyl acetamide in resisting mycobacterium tuberculosis infection 厦门大学 2022-08-23 CN claimed
CN-108299251-B Preparation method of glimepiride impurity 山东新华制药股份有限公司 2020-10-30 CN claimed
CN-110403931-A 5- Sunkatol No. 1 replaces medical usage of the N- phenethyl-acetamide in Killing Mycobacterium Tuberculosis infection UNIV XIAMEN 2019-11-05 CN claimed
US-8148537-B2 Substituted acetophenones useful as PDE4 inhibitors LEO PHARMA A/S (DK) 2012-04-03 US claimed
EP-0853618-B1 SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS AVENTIS PHARMA INC (US) 2011-08-17 EP claimed
EP-2125736-B1 SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS LEO PHARMA AS (DK) 2011-03-30 EP claimed
US-20100331348-A1 TROPANE DERIVATIVES USEFUL AS PESTICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-12-30 US claimed
US-20100204265-A1 Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections GENELABS TECHNOLOGIES, INC. 2010-08-12 US claimed
CN-1910144-B Sulfonamide derivatives for the treatment of diseases PFIZER LTD 2010-06-09 CN claimed
EP-0594608-A1 CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. RES CORP TECHNOLOGIES INC (US) 1994-05-04 EP claimed
EP-0280443-B1 Improvements in or relating to repellent compositions DALGETY LTD (GB) 1994-04-20 EP claimed
EP-0594608-A4 CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESIS. RES CORP TECHNOLOGIES INC (US) 1993-03-15 EP claimed
EP-0192492-B1 PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1992-01-02 EP claimed
EP-0238357-B1 1,2,4-TRIAZINONE DERIVATIVES, THEIR PREPARATION AND USE Sankyo Company Limited (JP) 1991-05-29 EP claimed
EP-0280443-A2 Improvements in or relating to repellent compositions DALGETY U.K. LIMITED (GB) 1988-08-31 EP claimed
US-4650910-A CLEAVAGE OF N-ACYL-B-PHENETHYLAMINES WITH BASE BAYER AKTIENGESELLSCHAFT (DE) 1987-03-17 US claimed
EP-0009608-B1 N-PHENETHYLACETAMIDE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THEM DAIICHI SEIYAKU CO., LTD. (JP) 1982-04-21 EP claimed
US-4297357-A ANTIULCER AGENTS; ANTISECRETORY AGENTS DAIICHI SEIYAKU CO., LTD. (JP) 1981-10-27 US claimed
EP-0009608-A1 N-Phenethylacetamide compounds, processes for their preparation and therapeutic compositions containing them DAIICHI SEIYAKU CO., LTD. (JP) 1980-04-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204265-A1 Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections OAT, HAVCR2, CPS1 KDM4E 2131/4885F13A1 4103/4885SMN1; SMN2 3448/4885
US-20100331348-A1 TROPANE DERIVATIVES USEFUL AS PESTICIDES DDT, ACHE, TPM3 KDM4E 3763/4885F13A1 3965/4885SMN1; SMN2 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.